CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2018-11, Vol.36 (33), p.JCO2018783118-3297
Hauptverfasser: Reungwetwattana, Thanyanan, Nakagawa, Kazuhiko, Cho, Byoung Chul, Cobo, Manuel, Cho, Eun Kyung, Bertolini, Alessandro, Bohnet, Sabine, Zhou, Caicun, Lee, Ki Hyeong, Nogami, Naoyuki, Okamoto, Isamu, Leighl, Natasha, Hodge, Rachel, McKeown, Astrid, Brown, Andrew P, Rukazenkov, Yuri, Ramalingam, Suresh S, Vansteenkiste, Johan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3297
container_issue 33
container_start_page JCO2018783118
container_title Journal of clinical oncology
container_volume 36
creator Reungwetwattana, Thanyanan
Nakagawa, Kazuhiko
Cho, Byoung Chul
Cobo, Manuel
Cho, Eun Kyung
Bertolini, Alessandro
Bohnet, Sabine
Zhou, Caicun
Lee, Ki Hyeong
Nogami, Naoyuki
Okamoto, Isamu
Leighl, Natasha
Hodge, Rachel
McKeown, Astrid
Brown, Andrew P
Rukazenkov, Yuri
Ramalingam, Suresh S
Vansteenkiste, Johan
description Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients with asymptomatic or stable CNS metastases were included. In patients with symptomatic CNS metastases, neurologic status was required to be stable for ≥ 2 weeks after completion of definitive therapy and corticosteroids. A preplanned subgroup analysis with CNS progression-free survival as primary objective was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review. The CNS evaluable-for-response set included patients with ≥ one measurable CNS lesion. Results Of 200 patients with available brain scans at baseline, 128 (osimertinib, n = 61; standard EGFR-TKIs, n = 67) had measurable and/or nonmeasurable CNS lesions, including 41 patients (osimertinib, n = 22; standard EGFR-TKIs, n = 19) with ≥ one measurable CNS lesion. Median CNS progression-free survival in patients with measurable and/or nonmeasurable CNS lesions was not reached with osimertinib (95% CI, 16.5 months to not calculable) and 13.9 months (95% CI, 8.3 months to not calculable) with standard EGFR-TKIs (hazard ratio, 0.48; 95% CI, 0.26 to 0.86; P = .014 [nominally statistically significant]). CNS objective response rates were 91% and 68% in patients with ≥ one measurable CNS lesion (odds ratio, 4.6; 95% CI, 0.9 to 34.9; P = .066) and 66% and 43% in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.
doi_str_mv 10.1200/JCO.2018.78.3118
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2096560453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2096560453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-5926266089bd5daa915b535b9694d36599e20c84c880aae63fa21cd0a339626a3</originalsourceid><addsrcrecordid>eNo9kU1v1DAQhi0Eokvhzgn5yCVbf6wT-1hF3aWwdFG3BW6W48xSo8RJbQfU38UfrNOWnjzWzPOO5Qeh95QsKSPk5HO9WzJC5bKSS06pfIEWVLCqqCohXqIFqTgrqOQ_j9CbGH8TQleSi9foiBMqOFHVAv2rL_b4EuI4-Ag4DXgXXQ8hOe8a_B1CnCLeJ-NbE1p8NroWQm86vAnD33SD18amIWTewjgXV3dhiM4D_uK8yXnn_sY1Lncidh5_M8mBTxH_cJm99imASZBjN-vL4uuUHi6n7R_jbS4uBl_s866uqKHr8Hbyv3A9t8Jb9Opgugjvns5jdL0-u6o_Fdvd5rw-3RaWS5kKoVjJypJI1bSiNUZR0QguGlWqVctLoRQwYuXKSkmMgZIfDKO2JYZzlUHDj9HHx9wxDLcTxKR7F21-jPEwTFEzokpRkpXgeZQ8jtr8ATHAQY_B9SbcaUr0rEpnVXpWpSupZ1UZ-fCUPjU9tM_Afzf8HgtFkKE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2096560453</pqid></control><display><type>article</type><title>CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</title><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Reungwetwattana, Thanyanan ; Nakagawa, Kazuhiko ; Cho, Byoung Chul ; Cobo, Manuel ; Cho, Eun Kyung ; Bertolini, Alessandro ; Bohnet, Sabine ; Zhou, Caicun ; Lee, Ki Hyeong ; Nogami, Naoyuki ; Okamoto, Isamu ; Leighl, Natasha ; Hodge, Rachel ; McKeown, Astrid ; Brown, Andrew P ; Rukazenkov, Yuri ; Ramalingam, Suresh S ; Vansteenkiste, Johan</creator><creatorcontrib>Reungwetwattana, Thanyanan ; Nakagawa, Kazuhiko ; Cho, Byoung Chul ; Cobo, Manuel ; Cho, Eun Kyung ; Bertolini, Alessandro ; Bohnet, Sabine ; Zhou, Caicun ; Lee, Ki Hyeong ; Nogami, Naoyuki ; Okamoto, Isamu ; Leighl, Natasha ; Hodge, Rachel ; McKeown, Astrid ; Brown, Andrew P ; Rukazenkov, Yuri ; Ramalingam, Suresh S ; Vansteenkiste, Johan</creatorcontrib><description>Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients with asymptomatic or stable CNS metastases were included. In patients with symptomatic CNS metastases, neurologic status was required to be stable for ≥ 2 weeks after completion of definitive therapy and corticosteroids. A preplanned subgroup analysis with CNS progression-free survival as primary objective was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review. The CNS evaluable-for-response set included patients with ≥ one measurable CNS lesion. Results Of 200 patients with available brain scans at baseline, 128 (osimertinib, n = 61; standard EGFR-TKIs, n = 67) had measurable and/or nonmeasurable CNS lesions, including 41 patients (osimertinib, n = 22; standard EGFR-TKIs, n = 19) with ≥ one measurable CNS lesion. Median CNS progression-free survival in patients with measurable and/or nonmeasurable CNS lesions was not reached with osimertinib (95% CI, 16.5 months to not calculable) and 13.9 months (95% CI, 8.3 months to not calculable) with standard EGFR-TKIs (hazard ratio, 0.48; 95% CI, 0.26 to 0.86; P = .014 [nominally statistically significant]). CNS objective response rates were 91% and 68% in patients with ≥ one measurable CNS lesion (odds ratio, 4.6; 95% CI, 0.9 to 34.9; P = .066) and 66% and 43% in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2018.78.3118</identifier><identifier>PMID: 30153097</identifier><language>eng</language><publisher>United States</publisher><ispartof>Journal of clinical oncology, 2018-11, Vol.36 (33), p.JCO2018783118-3297</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-5926266089bd5daa915b535b9694d36599e20c84c880aae63fa21cd0a339626a3</citedby><cites>FETCH-LOGICAL-c388t-5926266089bd5daa915b535b9694d36599e20c84c880aae63fa21cd0a339626a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3716,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30153097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reungwetwattana, Thanyanan</creatorcontrib><creatorcontrib>Nakagawa, Kazuhiko</creatorcontrib><creatorcontrib>Cho, Byoung Chul</creatorcontrib><creatorcontrib>Cobo, Manuel</creatorcontrib><creatorcontrib>Cho, Eun Kyung</creatorcontrib><creatorcontrib>Bertolini, Alessandro</creatorcontrib><creatorcontrib>Bohnet, Sabine</creatorcontrib><creatorcontrib>Zhou, Caicun</creatorcontrib><creatorcontrib>Lee, Ki Hyeong</creatorcontrib><creatorcontrib>Nogami, Naoyuki</creatorcontrib><creatorcontrib>Okamoto, Isamu</creatorcontrib><creatorcontrib>Leighl, Natasha</creatorcontrib><creatorcontrib>Hodge, Rachel</creatorcontrib><creatorcontrib>McKeown, Astrid</creatorcontrib><creatorcontrib>Brown, Andrew P</creatorcontrib><creatorcontrib>Rukazenkov, Yuri</creatorcontrib><creatorcontrib>Ramalingam, Suresh S</creatorcontrib><creatorcontrib>Vansteenkiste, Johan</creatorcontrib><title>CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients with asymptomatic or stable CNS metastases were included. In patients with symptomatic CNS metastases, neurologic status was required to be stable for ≥ 2 weeks after completion of definitive therapy and corticosteroids. A preplanned subgroup analysis with CNS progression-free survival as primary objective was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review. The CNS evaluable-for-response set included patients with ≥ one measurable CNS lesion. Results Of 200 patients with available brain scans at baseline, 128 (osimertinib, n = 61; standard EGFR-TKIs, n = 67) had measurable and/or nonmeasurable CNS lesions, including 41 patients (osimertinib, n = 22; standard EGFR-TKIs, n = 19) with ≥ one measurable CNS lesion. Median CNS progression-free survival in patients with measurable and/or nonmeasurable CNS lesions was not reached with osimertinib (95% CI, 16.5 months to not calculable) and 13.9 months (95% CI, 8.3 months to not calculable) with standard EGFR-TKIs (hazard ratio, 0.48; 95% CI, 0.26 to 0.86; P = .014 [nominally statistically significant]). CNS objective response rates were 91% and 68% in patients with ≥ one measurable CNS lesion (odds ratio, 4.6; 95% CI, 0.9 to 34.9; P = .066) and 66% and 43% in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.</description><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo9kU1v1DAQhi0Eokvhzgn5yCVbf6wT-1hF3aWwdFG3BW6W48xSo8RJbQfU38UfrNOWnjzWzPOO5Qeh95QsKSPk5HO9WzJC5bKSS06pfIEWVLCqqCohXqIFqTgrqOQ_j9CbGH8TQleSi9foiBMqOFHVAv2rL_b4EuI4-Ag4DXgXXQ8hOe8a_B1CnCLeJ-NbE1p8NroWQm86vAnD33SD18amIWTewjgXV3dhiM4D_uK8yXnn_sY1Lncidh5_M8mBTxH_cJm99imASZBjN-vL4uuUHi6n7R_jbS4uBl_s866uqKHr8Hbyv3A9t8Jb9Opgugjvns5jdL0-u6o_Fdvd5rw-3RaWS5kKoVjJypJI1bSiNUZR0QguGlWqVctLoRQwYuXKSkmMgZIfDKO2JYZzlUHDj9HHx9wxDLcTxKR7F21-jPEwTFEzokpRkpXgeZQ8jtr8ATHAQY_B9SbcaUr0rEpnVXpWpSupZ1UZ-fCUPjU9tM_Afzf8HgtFkKE</recordid><startdate>20181120</startdate><enddate>20181120</enddate><creator>Reungwetwattana, Thanyanan</creator><creator>Nakagawa, Kazuhiko</creator><creator>Cho, Byoung Chul</creator><creator>Cobo, Manuel</creator><creator>Cho, Eun Kyung</creator><creator>Bertolini, Alessandro</creator><creator>Bohnet, Sabine</creator><creator>Zhou, Caicun</creator><creator>Lee, Ki Hyeong</creator><creator>Nogami, Naoyuki</creator><creator>Okamoto, Isamu</creator><creator>Leighl, Natasha</creator><creator>Hodge, Rachel</creator><creator>McKeown, Astrid</creator><creator>Brown, Andrew P</creator><creator>Rukazenkov, Yuri</creator><creator>Ramalingam, Suresh S</creator><creator>Vansteenkiste, Johan</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181120</creationdate><title>CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</title><author>Reungwetwattana, Thanyanan ; Nakagawa, Kazuhiko ; Cho, Byoung Chul ; Cobo, Manuel ; Cho, Eun Kyung ; Bertolini, Alessandro ; Bohnet, Sabine ; Zhou, Caicun ; Lee, Ki Hyeong ; Nogami, Naoyuki ; Okamoto, Isamu ; Leighl, Natasha ; Hodge, Rachel ; McKeown, Astrid ; Brown, Andrew P ; Rukazenkov, Yuri ; Ramalingam, Suresh S ; Vansteenkiste, Johan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-5926266089bd5daa915b535b9694d36599e20c84c880aae63fa21cd0a339626a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reungwetwattana, Thanyanan</creatorcontrib><creatorcontrib>Nakagawa, Kazuhiko</creatorcontrib><creatorcontrib>Cho, Byoung Chul</creatorcontrib><creatorcontrib>Cobo, Manuel</creatorcontrib><creatorcontrib>Cho, Eun Kyung</creatorcontrib><creatorcontrib>Bertolini, Alessandro</creatorcontrib><creatorcontrib>Bohnet, Sabine</creatorcontrib><creatorcontrib>Zhou, Caicun</creatorcontrib><creatorcontrib>Lee, Ki Hyeong</creatorcontrib><creatorcontrib>Nogami, Naoyuki</creatorcontrib><creatorcontrib>Okamoto, Isamu</creatorcontrib><creatorcontrib>Leighl, Natasha</creatorcontrib><creatorcontrib>Hodge, Rachel</creatorcontrib><creatorcontrib>McKeown, Astrid</creatorcontrib><creatorcontrib>Brown, Andrew P</creatorcontrib><creatorcontrib>Rukazenkov, Yuri</creatorcontrib><creatorcontrib>Ramalingam, Suresh S</creatorcontrib><creatorcontrib>Vansteenkiste, Johan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reungwetwattana, Thanyanan</au><au>Nakagawa, Kazuhiko</au><au>Cho, Byoung Chul</au><au>Cobo, Manuel</au><au>Cho, Eun Kyung</au><au>Bertolini, Alessandro</au><au>Bohnet, Sabine</au><au>Zhou, Caicun</au><au>Lee, Ki Hyeong</au><au>Nogami, Naoyuki</au><au>Okamoto, Isamu</au><au>Leighl, Natasha</au><au>Hodge, Rachel</au><au>McKeown, Astrid</au><au>Brown, Andrew P</au><au>Rukazenkov, Yuri</au><au>Ramalingam, Suresh S</au><au>Vansteenkiste, Johan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2018-11-20</date><risdate>2018</risdate><volume>36</volume><issue>33</issue><spage>JCO2018783118</spage><epage>3297</epage><pages>JCO2018783118-3297</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients with asymptomatic or stable CNS metastases were included. In patients with symptomatic CNS metastases, neurologic status was required to be stable for ≥ 2 weeks after completion of definitive therapy and corticosteroids. A preplanned subgroup analysis with CNS progression-free survival as primary objective was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review. The CNS evaluable-for-response set included patients with ≥ one measurable CNS lesion. Results Of 200 patients with available brain scans at baseline, 128 (osimertinib, n = 61; standard EGFR-TKIs, n = 67) had measurable and/or nonmeasurable CNS lesions, including 41 patients (osimertinib, n = 22; standard EGFR-TKIs, n = 19) with ≥ one measurable CNS lesion. Median CNS progression-free survival in patients with measurable and/or nonmeasurable CNS lesions was not reached with osimertinib (95% CI, 16.5 months to not calculable) and 13.9 months (95% CI, 8.3 months to not calculable) with standard EGFR-TKIs (hazard ratio, 0.48; 95% CI, 0.26 to 0.86; P = .014 [nominally statistically significant]). CNS objective response rates were 91% and 68% in patients with ≥ one measurable CNS lesion (odds ratio, 4.6; 95% CI, 0.9 to 34.9; P = .066) and 66% and 43% in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.</abstract><cop>United States</cop><pmid>30153097</pmid><doi>10.1200/JCO.2018.78.3118</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0732-183X
ispartof Journal of clinical oncology, 2018-11, Vol.36 (33), p.JCO2018783118-3297
issn 0732-183X
1527-7755
language eng
recordid cdi_proquest_miscellaneous_2096560453
source American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T15%3A47%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CNS%20Response%20to%20Osimertinib%20Versus%20Standard%20Epidermal%20Growth%20Factor%20Receptor%20Tyrosine%20Kinase%20Inhibitors%20in%20Patients%20With%20Untreated%20EGFR-Mutated%20Advanced%20Non-Small-Cell%20Lung%20Cancer&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Reungwetwattana,%20Thanyanan&rft.date=2018-11-20&rft.volume=36&rft.issue=33&rft.spage=JCO2018783118&rft.epage=3297&rft.pages=JCO2018783118-3297&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2018.78.3118&rft_dat=%3Cproquest_cross%3E2096560453%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2096560453&rft_id=info:pmid/30153097&rfr_iscdi=true